Mortality reduction in EMPA- REG OUTCOME trial: Beyond the antidiabetes effect

Diabetes Care

Volumn 41, Issue 2, 2018, Pages 219-223

  Suissa, Samy ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; CANAGLIFLOZIN; EMPAGLIFLOZIN; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PLACEBO; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ALL CAUSE MORTALITY; ANTIDIABETIC ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; DISEASE EXACERBATION; FOLLOW UP; HUMAN; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85041232661     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-1059     Document Type: Review

References (17)

1. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR- TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317–1326
2. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327–1335
3. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232–242
4. Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247–2257
5. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375: 311–322
6. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–1844
7. Zinman B, Wanner C, Lachin JM, et al.; EMPA- REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128
8. Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–657
9. McMurray J. EMPA- REG - the “diuretic hypothesis”. J Diabetes Complications 2016;30:3–4
10. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA- REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 2016;39: 1108–1114
11. Scheen AJ. Reduction in cardiovascular and all-cause mortality in the EMPA- REG OUTCOME trial: a critical analysis. Diabetes Metab 2016;42:71–76
12. Kaul S. Is the mortality benefit with empagliflozin in type 2 diabetes mellitus too good to be true? Circulation 2016;134:94–96
13. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009;32(Suppl. 2):S151–S156
14. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and micro-vascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405–412
15. Azoulay L, Suissa S. Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care 2017;40:706–714
16. Gamble JM, Simpson SH, Eurich DT, Majumdar SR, Johnson JA. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab 2010;12:47–53
17. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 2013;98:668–677